BRIDGEPORT HOSPITAL

The global cancer-focused genetic testing services market is projected to grow from USD 8,472.70 million in 2024 to USD 19.3 billion by 2034, driven by rising cancer cases, advancements in NGS technology, and declining testing costs. Key markets include the US, UK, India, and China, with significant growth potential. The market is competitive, with established and emerging firms innovating for market share.